Revenio Group Oyj

Latest Results (20.04.2026):

Revenio Group Oyj — Q4 2023: Revenio Group Oyj reported solid fourth-quarter 2023 results with net sales of EUR 29.1m (up 3.1% YoY) and strong profitability (operating profit EUR 9.5m, 32.6% margin). The company also published its full-year 2023 results: net sales EUR 96.6m (‑0.4% reported; +2.2% currency‑adjusted), operating profit EUR 26.3m (down 11.3%), and earnings per share EUR 0.719. Management proposed a EUR 0.38 dividend for 2024 and issued guidance for 2024 net‑sales growth of 5–10% (currency‑adjusted) with profitability expected to remain at a good level (ex. non‑recurring items).

Q4 revenue and profitability

October–December 2023 net sales EUR 29.1m (+3.1% vs Q4 2022). Operating profit EUR 9.5m (32.6% margin; +1.6% YoY). EBITDA EUR 10.5m (36.1% of sales; +3.1% YoY). EPS for Q4 was EUR 0.270 versus EUR 0.214 a year earlier.

Full‑year performance (FY 2023)

Full‑year net sales EUR 96.6m (‑0.4% reported; +2.2% currency‑adjusted). Operating profit EUR 26.3m (‑11.3%); adjusted operating profit (excluding ~EUR 1.0m one‑time costs) EUR 27.3m (‑7.9%). EBITDA EUR 30.3m (‑8.5%). EPS EUR 0.719 (down from 0.818 in 2022).

Cash flow and balance sheet

Q4 cash flow from operations EUR 5.2m (weakened by higher sales receivables from a strong quarter). FY operating cash flow EUR 10.9m (down from EUR 23.2m), affected by working‑capital movements and higher taxes. Cash and cash equivalents EUR 21.5m (31.12.2023). Net debt was negative (net cash) at EUR ‑3.6m and equity ratio improved to 72.7%.

Product and market highlights

Strong Q4 sales for retinal imaging (iCare DRSplus, EIDON family) and intraocular pressure devices (iCare IC200, iCare ILLUME). Significant screening orders in Germany and notable orders in the United States; reimbursement application for iCare HOME2 submitted to CMS in the U.S.

Investments & R&D

R&D costs for 2023 were EUR 10.4m (10.8% of net sales), reflecting continued product development. Gross capital expenditure totaled EUR 5.8m for the year.

Capital allocation & shareholder returns

Dividend paid in 2023 was EUR 0.36 per share; Board proposes EUR 0.38 per share for payment after the 2024 AGM. The company retains capacity for acquisitions and balance‑sheet strength is emphasized.

Outlook & strategy

Financial guidance for 2024: exchange‑rate‑adjusted net sales growth of 5–10% and continued good profitability excluding non‑recurring items. Strategy 2024–2026 focuses on product innovation, connected predictive solutions, customer focus, people & culture, and sustainable profitable growth with a medium‑term target to grow three times faster than the market from 2025 onward.

Notable operational items & risks

FY 2023 included ~EUR 1.0m one‑time project costs that lowered reported profit. Management notes ongoing macroeconomic and geopolitical uncertainties, component availability and regulatory/reimbursement risks that could affect demand and operations.